Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Active not recruiting 3Withdrawn 2Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Dermatologic 2Genitourinary 1

Conditions

Melanoma 2Lung Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Nivolumab 18Ipilimumab 16pembrolizumab 15Cyclophosphamide 13trametinib 9Radiotherapy 8dabrafenib 6Interleukin-2 6sargramostim 5fludarabine phosphate 5aldesleukin 5Vemurafenib 5Peripheral Blood Stem Cell Transplantation 5Fluorouracil 5130-nm albumin-bound paclitaxel 5fludarabine 4Radiosurgery 4Melphalan 4Celecoxib 4encorafenib 3durvalumab 3binimetinib 3avelumab 3Vorinostat 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Leucovorin 3Granulocyte-Macrophage Colony-Stimulating Factor 3Cytarabine 3Capecitabine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Infliximab × Dermatologic × Clear all
NCT06646016 2025-12-26

EPIC

Therakos LLC

Phase 2 Withdrawn
DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02763761 2018-10-09

An Investigational Study of Infliximab With Prednisone or Methylprednisolone Versus Prednisone Combination Treatment in Immune Related or Severe Diarrhea in Patients Treated With Yervoy and/or Opdivo

Bristol-Myers Squibb

Phase 2 Withdrawn
DermatologicGenitourinaryThoracic

Carcinoma, Renal Cell, Lung Neoplasms, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡